Close

Pre-Open Movers: Bed Bath Crashes on Cohen Sale, Foot Locker Jumps on New CEO

Go back to Pre-Open Movers: Bed Bath Crashes on Cohen Sale, Foot Locker Jumps on New CEO

BofA Negative on HP Inc (HPQ), Dell Technologies (DELL) Ahead of Earnings

August 23, 2022 12:30 PM EDT

BofA analyst Wamsi Mohan is negative on both Dell Technologies (NYSE: DELL) and HP Inc (NYSE: HPQ) shares ahead of their earnings releases.

Dell is set to report F2Q23 earnings after market close on Thursday, August 25th, while HP Inc is set to post F3Q22 earnings results on Tuesday, August 29th.

In a research note on Dell, Mohan said it has cut its F23 revenue... More

OSI Systems (OSIS) PT Raised to $115 at Oppenheimer

August 22, 2022 3:23 PM EDT

Oppenheimer analyst Christopher Glynn raised the price target on OSI Systems (NASDAQ: OSIS) to $115.00 (from $110.00) while maintaining an Outperform rating following recent results.

The analyst commented, "OSIS's ~$6.14 FY23 guidance midpoint compares to our prior $6.40 estimate ($6.36E consensus), with a challenged 1Q/timing and expected... More

Morgan Stanley Comments on General Motors (GM) Reinstating the Dividend/Buybacks

August 22, 2022 10:11 AM EDT

Morgan Stanley analyst Adam Jonas reiterated an Equalweight rating and $42.00 price target on General Motors (NYSE: GM).

The analyst comments "GMs stock reacted positively to the announcement of restoring a dividend and resuming buybacks, driving one of the stocks strongest single-day... More

23andMe (ME) Down 16% as CFO Schoch Resigns

August 19, 2022 11:58 AM EDT

23andMe Holding Co. (NASDAQ: ME) is down more than 16.6% on Friday after Steven Schoch announced his intention to resign from the company as CFO effective September 1st, 2022. Schoch will remain employed by ME through September 30, 2022, during which time he will assist in the transition... More

Cowen Reiterates Outperform, $130 PT on Axsome Therapeutics (AXSM) Following FDA Approval

August 19, 2022 10:39 AM EDT

Cowen analyst Joseph Thome reiterated an Outperform rating and $130.00 price target on Axsome Therapeutics (NASDAQ: AXSM) following news that AXS-05 (Auvelity) has been approved for the treatment of MDD nearly one year after the therapy's initial PDUFA date.

The analyst... More

Bill.com Holdings Inc. (BILL) PT Raised to $200 at KeyBanc

August 19, 2022 9:24 AM EDT

KeyBanc analyst Josh Beck raised the price target on Bill.com Holdings Inc. (NYSE: BILL) to $200.00 (from $150.00) while maintaining an Overweight rating following strong results.

The analyst commented, "Bill.com reported a HSD revenue beat and guided FY23 revenue to $965M, above our... More